A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma

European Journal of Haematology

Volumn 74, Issue 3, 2005, Pages 267-270

  Stern, Martin ^a   Herrmann, R ^a   Rochlitz, C ^a   Dirnhofer, S ^b   Pless, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CD20; Epstein Barr virus; Hodgkin lymphoma; Post transplant lymphoproliferative disease; Rituximab

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CYCLOSPORIN A; DACARBAZINE; DOXORUBICIN; LATENT MEMBRANE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINDESINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASE REPORT; CHRONIC PYELONEPHRITIS; COMPUTER ASSISTED TOMOGRAPHY; CYSTITIS; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALE; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE;

EID: 14044277516     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00398.x     Document Type: Article

References (21)

1. OPELZ G, HENDERSON R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-1516.
2. STADLMANN S, FEND F, MOSER P, OBRIST P, GREIL R, DIRNHOFER S. Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx, in a renal allograft recipient: case report and review of literature. Hum Pathol 2001;32:1264-1268.
3. PENN I. Neoplastic complications of transplantation. Semin Respir Infect 1993;8:233-239.
4. CHETTY R, BIDDOLPH S, GATTER K. An immunohistochemical analysis of Reed-Sternberg-like cells in post-transplantation lymphoproliferative disorders: the possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin's disease and Reed-Sternberg-like cells in non-Hodgkin's lymphomas and reactive conditions. Hum Pathol 1997;28:493-498.
5. TZANKOV A, ZIMPFER A, PEHRS AC, LUGLI A, WENT P, MAURER R, PILERI S, DIRNHOFER S. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-1147.
6. TSAI DE, HARDY CL, TOMASZEWSKI JE, KOTLOFF RM, OLTOFF KM, SOMER BG, SCHUSTER SJ, PORTER DL, MONTONE KT, STADTMAUER EA. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076-1088.
7. HERZIG KA, JUFFS HG, NORRIS D et al. A single-centre experience of post-renal transplant lymphoproliferative disorder. Transpl Int 2003;16:529-536.
8. PAYA CV, FUNG JJ, NALESNIK MA et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-1525.
9. GANNE V, SIDDIQI N, KAMAPLATH B, CHANG CC, COHEN EP, BRESNAHAN BA, HARIHARAN S. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003;17:417-422.
10. MILPIED N, VASSEUR B, PARQUET N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(Suppl. 1):113-116.
11. OERTEL S, ZEIDLER K, GREFER J et al. Monotherapy with the anti-CD20 antibody Rituximab (Ritux) in patients with post-transplant lymphoproliferative disease (PTLD) results of a multicentre phase II study. Blood 2002;100:2250.
12. EBPG EGoRT. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002;17(Suppl. 4):31-33 & 35-36.
13. BIERMAN PJ, VOSE JM, LANGNAS AN, RIFKIN RM, HAUKE RJ, SMIR BN, GREINER TC. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996;7:265-270.
14. CRAVER RD, SCHEER WD, CORREA H, VEHASKARI VM, YU LC. Hodgkin lymphoma in a renal transplant recipient associated with low peripheral blood Epstein-Barr virus genome copies. Arch Pathol Lab Med 2001;125:1480-1482.
15. GARNIER JL, LEBRANCHU Y, DANTAL J et al. Hodgkin's disease after transplantation. Transplantation 1996;61:71-76.
16. GOYAL RK, McEVOY L, WILSON DB. Hodgkin disease after renal transplantation in childhood. J Pediatr Hematol Oncol 1996;18:392-395.
17. ARMITAGE JM, KORMOS RL, STUART RS, FRICKER FJ, GRIFFITH BP, NALESNIK M, HARDESTY RL, DUMMER JS. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10: 877-886.
18. DEACON EM, PALLESEN G, NIEDOBITEK G, CROCKER J, BROOKS L, RICKINSON AB, YOUNG LS. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177:339-349.
19. EKSTRAND BC, LUCAS JB, HORWITZ SM, FAN Z, BRESLIN S, HOPPE RT, NATKUNAM Y, BARTLETT NL, HORNING SJ. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289.
20. + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101:420-424.
21. CHOQUET S, LEBLOND V, HERBRECHT R et al. Efficacy and safety of Rituximab in B-Cell post transplantation lymphoproliferative disorders (B-PTLD): final results of a multicenter, open label, phase II trial (M 39037 TRIAL). Blood 2003;102:a986 (abstract).